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Abstract 
Background: S. epidermidis is a commensal of the human skin that has been 
implicated in infective endocarditis and infections involving implanted medical 
devices. S. epidermidis induces platelet aggregation by an unknown 
mechanism. The fibrinogen binding protein serine aspartate repeat G (SdrG) 
is present in 67-91% of clinical strains. Objectives: To determine if SdrG plays 
a role in platelet activation and if so investigate the role of fibrinogen in this 
mechanism. Methods: SdrG was expressed in a surrogate host, Lactococcus 
lactis, in order to investigate its role in the absence of other staphylococcal 
components. Platelet adhesion and platelet aggregation assays were 
employed. Results: L. lactis expressing SdrG stimulated platelet aggregation 
(lag time 2.9 ± 0.5 min) whereas the L. lactis control did not. L. lactis SdrG-
induced aggregation was inhibited by αIIbβ3 antagonists and aspirin. 
Aggregation was dependent on both fibrinogen and IgG, and the platelet IgG 
receptor FcγRIIa. Pre-incubation of the bacteria with Bβ-chain fibrinopeptide 
inhibited aggregation (delaying the lag time 6-fold), suggesting that fibrinogen 
acts as a bridging molecule. Platelets adhered to L. lactis SdrG in the 
absence of fibrinogen. Adhesion was inhibited by αIIbβ3 antagonists, 
suggesting that this direct interaction involves αIIbβ3. Investigation using 
purified fragments of SdrG revealed a direct interaction with the B-domains. 
An indirect mechanism mediated by the A domain involved both a fibrinogen 
and an IgG bridge. Conclusion: SdrG alone is sufficient to support platelet 
adhesion and aggregation through both direct and indirect mechanisms.  
 3 
Introduction 
Staphylococci are a major cause of intravascular infections that can be 
difficult to treat due to the high incidence of antibiotic-resistant strains. 
Staphylococci are divided into coagulase-positive strains such as 
Staphylococcus aureus and coagulase-negative strains such as 
Staphylococcus epidermidis. S. epidermidis is a major cause of hospital 
acquired infections of indwelling medical devices. Coagulase-negative 
staphylococci are the leading cause of blood stream infections [1] with S. 
epidermidis implicated in infective endocarditis (IE) [2, [3]. Although 
contamination of blood products is relatively rare, patients that receive blood 
or platelet preparations contaminated with S. epidermidis can deteriorate 
rapidly [4]. A significant number of pooled platelet preparations (0.19%) are 
contaminated with bacteria [5], 67% with S. epidermidis. 
 
Both S. aureus and S. epidermidis have been shown to induce platelet 
aggregation in vitro. S. aureus mediates platelet aggregation through multiple 
mechanisms, many involving fibrinogen binding proteins [6, [7, [8]. The 
mechanism involved in S. epidermidis-induced platelet aggregation is 
unknown. It was inhibited by treatment of the bacteria with trypsin [9], 
suggesting that a surface protein is involved, however the protein or proteins 
involved have not been identified. 
 
The serine aspartate repeat protein SdrG of S. epidermidis is a Microbial 
Surface Component Recognising Adhesive Matrix Molecules (MSCRAMM) 
that binds fibrinogen. It is also known as Fbe. Deletion of the sdrG (fbe) gene 
led to decreased adhesion to fibrinogen-coated surfaces [10], and antibodies 
to SdrG(Fbe) have been shown to inhibit S. epidermidis adhesion on 
implanted polyethylene catheters [11]. These data suggest that SdrG is the 
predominant fibrinogen binding protein on S. epidermidis. SdrG’s closest 
homologue is the Staphylococcus aureus surface protein, SdrE, which can 
stimulate platelet aggregation in platelet rich plasma (PRP) with a long lag 
time (13.5 ± 3.5 min) [12]. SdrE does not bind to fibrinogen, and we have 
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shown the platelet activation mechanism to be complement dependent 
(Brennan et al., unpublished data). Other homologues on the surface of S. 
aureus involved in platelet activation include the clumping factors ClfA and 
ClfB and the fibronectin binding proteins FnBPA and FnBPB. These four 
surface proteins stimulate a faster platelet aggregation dependent on the 
binding of fibrinogen and IgG [6, [7, [8] (the FnBP’s can also use fibronectin 
instead of fibrinogen).  
 
ClfA and the FnBP’s bind to the C-terminus of the γ-chain of fibrinogen [13, 
[14] while ClfB binds to the C-terminus of the α-chain [15, [16]. SdrG binds to 
the N-terminus of the Bβ chain (residues 6-20) of fibrinogen  [17, [18, [19]. 
SdrG has the same structural organization as the S. aureus Clf-Sdr family of 
surface proteins [20, [21]. Its extracellular domain is made up of a serine-
aspartate repeat region (SD domain), two B-domains and the fibrinogen 
binding A domain. Ponnuraj et al. reported the crystal structure of the ligand 
binding A domain of SdrG in complex with the fibrinogen Bβ chain N-terminal 
peptide [21]. The fibrinopeptide was bound in the groove between the N2 and 
N3 subdomains. The authors demonstrated that the native fibrinopeptide 
(NEEGFFSARGHRPLD) inhibited SdrG binding to fibrinogen. They also 
showed that when the underlined serine was replaced by an alanine, the 
resulting peptide could not inhibit fibrinogen binding. We have used these 
peptides to investigate the role of fibrinogen in the interaction with platelets. 
 
We postulated that SdrG may mediate S. epidermidis-induced platelet 
aggregation in a manner similar to other fibrinogen-binding MSCRAMMS 
found on S. aureus. In this study, we examined the mechanism of platelet 
activation stimulated by SdrG. We have demonstrated that two distinct 
interactions are involved; (i) a direct interaction involving αIIbβ3 and (ii) an 
indirect mechanism involving fibrinogen, IgG and the platelet FcγRIIa receptor. 
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Methods 
 
All compounds were purchased from Sigma Aldrich UK unless stated 
otherwise. 
Platelet Preparation 
Blood was collected using a 19-gauge needle from healthy volunteers who 
had not taken non-steroidal anti-inflammatory drugs during the previous 
fortnight, without discrimination based on age or sex. Ethical approval was 
obtained from the RCSI ethics committee. Gel filtered platelets (GFP) and 
platelet rich plasma (PRP) were prepared as described by Loughman et al [7]. 
The GFPs were diluted to 3 x 108 platelets per ml and supplemented with 
CaCl2 and fibrinogen (Calbiochem, Germany) to final concentrations of 2 µM, 
and 1 mg/ml, respectively, prior to aggregometry. Platelet counts within the 
range of 2-4.5 x 108 platelets per ml were used in PRP platelet aggregations. 
Platelet aggregations were carried out using a PAP-4 aggregometer (Biodata 
Corporation, PA, USA). 100% aggregation represents the light transmission 
equivalent to the platelet poor plasma control in PRP aggregations, and the 
buffer control for GFP aggregations. 50µl of bacterial suspension (OD600 1.6) 
corresponding to 1 x 108 bacteria was added to 450µl of PRP or GFPs and 
incubated at 37°C stirring at 1200 rpm while measuring light transmission. 
Aggregations were recorded for a maximum of 30 min. 
Inhibition Studies 
Platelets were incubated with antibodies or inhibitors for 10 min at 37°C prior 
to the addition of platelet agonists. The inhibitory antibody to GPIIb (CD41), 
abciximab (Eli Lilly, Indiana, USA), was used at 20 µg/ml. Tirofiban was used 
at 1 µM, and aspirin at 1 mM (pre-incubation for 5 min). The inhibitory 
antibody to the FcγRIIa, IV.3 (StemCell Technologies, Vancouver, Canada) 
was used at 10 µg/ml. 
 6 
Platelet Adhesion assay 
Platelets were prepared by gel filtration as described above. Bacteria were 
coated onto a 96-well microtiter plate at an OD600 of 1.0 for 2 h at 37°C 
followed by blocking in 1% BSA for 2 h at 37°C. Plates were washed twice in 
JNL (6 mM dextrose, 130 mM NaCl, 9 mM NaHCO3, 10 mM Na citrate, 10 
mM Tris base, 3 mM KCl, 0.8 mM KH2PO4 and 0.9 mM MgCl2 pH 7.4), and 50 
µl of platelets (2 x 108/ml) were added and incubated for 30 min at 37°C. 
Plates were washed twice in JNL, and lysed in 0.1 M sodium acetate, 0.1% 
Triton X-100 and 10mM p-nitrophenol phosphate (Pierce, Rockford, IL, USA) 
for 90 min at 37°C. The plates were read at an absorbance of 405 nm [22]. 
Depletion of BSA antibodies from pooled human IgG 
Gammaguard (Baxter, IL, USA) was depleted of BSA antibodies prior to 
supplementation into platelet adhesion assays. 6-well plates were coated with 
1% BSA in TBS for 2 hours at 37 °C. The plates were washed three times 
with TBS prior to incubation with 500 µg/ml Gammaguard for 30 min at 37°C. 
The depleted Gammaguard was removed and stored for use in adhesion 
assays. Gammaguard IgG and fibrinogen were both used at 50 µg/ml and 
incubated for 30 min at 37°C prior to platelet adhesions, where indicated.  
Bacterial Growth Conditions 
Lactococcus lactis MG1363 control and the L. lactis expressing SdrE or SdrG 
were grown as static cultures at 30°C in M17 broth (Oxoid U.K.) 
supplemented with 0.5% glucose and 5 µg/ml erythromycin. 
 
Staphylococcus epidermidis was grown as static cultures in TSB broth (Difco) 
at 37°C. S. epidermidis overnight starter culture (2 ml) was seeded into 48 ml 
of TSB broth and incubated at 37°C for 2 hours to grow bacteria to 
exponential phase. S. epidermidis strain 19 was a kind gift from Prof. J.I. 
Flock, Karolinska Institutet, Huddinge University Hospital, Sweden.  
Bacterial Preparation 
Bacterial cultures were centrifuged at 5,000 x g for 10 min. The broth was 
discarded, the pellets washed in PBS, and centrifuged again at 5,000 x g for a 
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further 10 min. The resulting pellets were resuspended in PBS to the relevant 
optical density (OD), measured using the Ultrospec III spectrophotometer 
(Pharmacia Biotech U.K.), at 600nm. The optical density, (OD600) of 1.6 
corresponds to 7 x 109 colony forming units (CFU), and OD600 of 1.0 
corresponds to 3 x 109 CFU. 
Bacterial Adhesion Assays 
Adhesion assays were carried out according to Hartford et al [23]. Briefly, 
plates were coated with fibrinogen (Calbiochem, Darmstadt, Germany) for 2 h 
at 37°C or for 16 h at 4°C. Plates were blocked with 1% BSA at 37°C for 1 h, 
and washed 3 times in PBS. Bacteria were incubated at 37°C for 2 h at an 
OD600 of 1. Adherent bacteria were washed three times in PBS, and fixed in 
25% formaldehyde at room temperature for 30 min. Wells were washed three 
times in PBS, and stained using 5% crystal violet for 10 min. Wells were 
washed three times in PBS, and the crystal violet solubilized using 5% acetic 
acid. Plates were read at 620 nm using a Wallac Victor2, (Shelton, 
Connecticut, USA).   
Peptide Synthesis 
Peptides were prepared by Solid Phase Peptide Synthesis [24]. Peptide 
masses were confirmed by Matrix Assisted Laser Desorption Ionisation – 
Time Of Flight (MALDI-TOF) and peptide purity was determined to be greater 
than 95% for all experiments. 
Synthesis and Purification of Recombinant SdrG Fragments 
The putative ligand binding A domain of SdrG and the B1-B2 domain was 
expressed in Escherichia coli TOPP3 with a hexahistidine tag at the N-
terminus [12]. Recombinant proteins were purified using Ni2+ chelate 
chromatography [25].  
Statistics 
Statistics were carried out using InStat version 3 (Graphpad Software Inc.). 
Experiments were carried out 3-5 times and data analysed by ordinary 
ANOVA followed by the Dunnett’s test unless otherwise stated. When there 
were only two data sets to be compared, a paired two-tailed student’s T-test 
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was carried out. P values less than 0.05 were considered significant and have 
been illustrated with a single star. Values less than 0.01 were considered 
highly significant, illustrated with a double star. Repeated measures ANOVA 
was carried out where the data was paired. 
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Results 
Platelet Aggregation in PRP 
The wild type S. epidermidis strain 19 is known to express SdrG in the 
exponential phase of growth [26]. These bacteria stimulated platelet 
aggregation (67 ± 10%; n=3), with a lag time of 7.8 ± 3.5 min (time taken from 
the addition of bacteria to the beginning of the aggregation response; Table 
1). When SdrG was over-expressed on the surrogate host L. lactis, platelets 
were activated with a shorter lag time of 2.9 ± 0.5 min (73 ± 9%). These 
aggregations were completely inhibited (no aggregation within 30 min) by the 
αIIbβ3 antagonists abciximab and tirofiban, and also by aspirin, (0.3 ± 0.3%, 
0.7 ± 0.7% and 16 ± 6% respectively data not shown). These data suggest 
that this was true aggregation and not agglutination. The host bacteria L. 
lactis, which does not express SdrG, did not support aggregation and was 
used as a control (no aggregation after 30 min, 0.3 ± 0.3%).  
 
Role of Fibrinogen Binding in SdrG-induced Platelet Aggregation 
In order to investigate the role of fibrinogen in SdrG-induced platelet 
aggregation, we used the N-terminal peptide derived from Bβ chain fibrinogen 
peptide, NEEGFFSARGHRPLD, (SAR), which has been shown to inhibit 
binding of recombinant SdrG to fibrinogen [21]. The authors demonstrated 
that when the serine was replaced with an alanine, NEEGFFAARGHRPLD, 
(AAR), the variant peptide did not inhibit the SdrG-fibrinogen interaction. We 
thus used this peptide as a control. The peptides that we synthesised for this 
study displayed the same activity. The SAR peptide (100 µM) inhibited 
adhesion of L. lactis SdrG to immobilized fibrinogen by 81.6 ± 3.4% (P < 0.05) 
while the control AAR peptide had no significant effect; 8.0 ± 4.2% inhibition 
(data not shown).  
 
Incubation of L. lactis expressing SdrG with the native SAR peptide (5 mM) 
delayed the lag time to platelet aggregation from 1.6 ± 0.4 min to 8.9 ± 1.7 
min (P < 0.05; figure 1A). The control AAR peptide had no effect on platelet 
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aggregation (with 5 mM the lag time was 1.1 ± 0.5 min). The SAR peptide 
reached a maximum effect at 5 mM (figure 1B) whereas no significant effect 
was seen with the control AAR peptide even at 10 mM (lag time 2.7 ± 1.2 
min). These peptides had no significant effect on platelet aggregation 
stimulated by L. lactis SdrE (lag times 10.9 ± 1.8 min, SAR-treated 9.8 ± 3.5 
min, AAR-treated 10.5 ± 4.0 min, figure 1A). These peptides also had no 
significant effect on aggregation promoted by S. aureus Newman (lag times 
0.5 ± 0.1 min, SAR-treated 0.5 ± 0.1 min, AAR-treated 0.5 ± 0.1 min, figure 
1A). Figure 1C is a representative aggregation trace demonstrating the effect 
of the peptides on platelet aggregation induced by L. lactis SdrG. These 
peptides also had no effect on arachidonic acid induced platelet aggregation. 
Role of IgG in SdrG Mediated Platelet Aggregation 
L. lactis SdrG failed to induce aggregation of washed platelets alone or 
supplemented with fibrinogen (figure 2A). However, the addition of both 
fibrinogen and IgG to washed platelets was sufficient to support platelet 
aggregation. Furthermore pre-coating the bacteria with IgG and 
supplementing with soluble fibrinogen also supported aggregation, 
demonstrating that the IgG was bound to the surface of the bacteria during 
aggregation. The percentage aggregation and lag times taken to aggregation 
is summarized in figure 2C. A representative platelet aggregation trace 
depicting aggregation stimulated by L. lactis SdrG when supplemented with 
fibrinogen and IgG is shown in figure 2D. The L. lactis control did not stimulate 
aggregation under these conditions. The dependence on IgG led us to 
investigate the role of the platelet IgG receptor, FcγRIIa. L. lactis SdrG-
induced aggregation was inhibited by a monoclonal antibody directed against 
the FcγRIIa, IV.3, figure 2B; L. lactis SdrG aggregation 58.0 ± 5.7%, IV.3 
treated 2.3 ± 0.3%, P < 0.01; L. lactis SdrG lag time 2.3 ± 1.1 min, IV.3 treated 
did not aggregate after 30 min). 
Platelet Adhesion to SdrG 
Immobilized S. epidermidis 19 supported platelet adhesion of washed 
platelets (106 ± 4.5% of the immobilized fibrinogen control). L. lactis SdrG  
also supported platelet adhesion (209 ± 65%) while the L. lactis control failed 
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to support platelet adhesion (7.9 ± 3.0%); figure 3). Adhesion of washed 
platelets to immobilized L. lactis SdrG was inhibited by the αIIbβ3 antagonists, 
abciximab (24.9 ± 16.4%, P < 0.05) and tirofiban (35.8 ±14.6%, P < 0.05), 
suggesting a direct interaction between SdrG and αIIbβ3. Subsequently, we 
purified the recombinant A and B domains of SdrG (figure 4) in order to further 
localise the platelet binding region of SdrG. Platelet adhesion to the 
immobilized A domain was weak (18 ± 7% of the fibrinogen control). This 
adhesion was enhanced by the addition of fibrinogen or IgG alone, (30 ± 8%, 
41 ± 10% respectively) and together 52 ± 6% (P < 0.01 for all). The 
immobilized B domain supported platelet adhesion at 33 ± 4% of the 
fibrinogen control. This adhesion was not significantly enhanced by the 
presence of fibrinogen or IgG, added prior to the platelets (figure 5A, 
fibrinogen only, 34 ± 6%; IgG only, 43 ± 9%; fibrinogen and IgG, 39 ± 7%). 
The αIIbβ3 antagonist tirofiban inhibited adhesion to the B-domain by 78.3% (P 
< 0.05) suggesting that RGD binding site on the integrin is involved (figure 
5B). These purified proteins did not stimulate aggregation in platelet rich 
plasma (PBS control 2.7 ± 0.3%, A-domain 3.7 ± 0.9%, B-domain 5.3 ± 0.9%, 
percentages measured at 10 min, n=3, data not shown). 
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Discussion 
SdrG is present in 67-91% of clinical strains [27]. A recent study 
demonstrated that SdrG expression was induced in a strain that did not 
express detectable levels of SdrG in vitro, after injection into the blood stream 
of mice [28]. Furthermore, McCrea et al. have shown that patients recovering 
from S. epidermidis infections have an increased antibody titer for SdrG when 
compared to age matched controls [29]. This suggests that SdrG is expressed 
on the surface of S. epidermidis during infection, and is thus clinically 
important. 
 
Wild type S. epidermidis strain 19 induced platelet aggregation which is likely 
due to the presence of SdrG that is known to be expressed on its surface [26]. 
L. lactis SdrG induced platelet aggregation, although with a shorter lag time. 
This difference in lag time is probably due to the increased levels of SdrG in L. 
lactis SdrG. We have previously shown that the level of expression of a pro-
aggregatory surface protein is an important determinant of lag time [7]. 
Platelet aggregation was inhibited by αIIbβ3 antagonists and aspirin suggesting 
that SdrG stimulates true aggregation via αIIbβ3 that is dependent on 
cyclooxygenase signaling.  
 
The N-terminal peptide of the Bβ chain of fibrinogen NEEGFFSARGHRPLD 
has been shown to inhibit fibrinogen binding to SdrG. Addition of this peptide 
allowed us to study the effects of SdrG on platelet function in the absence of 
fibrinogen binding to the bacterial surface while maintaining fibrinogen levels 
necessary to support platelet aggregation. Addition of the SAR peptide 
prolonged the lag time of L. lactis SdrG-induced platelet aggregation 6-fold to 
8.9 ± 1.7 min. SdrE is a homologous protein to SdrG that is found on S. 
aureus which induced platelet aggregation with a similarly long lag time of 
10.9 ± 1.8 min this study, (13.5 ± 3.5 min [12]). Thus inhibition of the SdrG 
fibrinogen mechanism delays the lag time to L. lactis SdrG aggregation to a 
time similar to that taken to induce L. lactis SdrE aggregation. This result 
confirms that fibrinogen bound to the bacterial cell surface is required for rapid 
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platelet aggregation to take place. This is unlikely to be due to inadequate 
levels of the SAR peptide as the concentration used completely inhibited 
fibrinogen binding and increasing the concentration further did not prolong the 
lag time further.  
 
The fact that inhibition of fibrinogen binding could only prolong the lag time 
and not prevent platelet aggregation suggests that both SdrE and SdrG have 
a fibrinogen-independent mechanism (probably complement-dependent) for 
platelet activation as was found for the S. aureus MSCRAMMs ClfA and ClfB 
[7, [8]. Bacteria expressing a ClfA or ClfB mutant which could not bind 
fibrinogen had a delayed lag time to aggregation and required complement 
fixation to occur on the cell surface [7, [8].  
 
The presence of fibrinogen alone was insufficient to support platelet 
aggregation because with washed platelets both fibrinogen and IgG were 
required (figure 2). This is analogous to the mechanism demonstrated for S. 
sanguis M99, S. salivarius D1 [30], the S. aureus surface proteins, ClfA [7], 
ClfB [8] and FnBPA [6], and S. pyrogenes M protein [31]. For all these 
bacteria, both fibrinogen and IgG are required for aggregation. In the case of 
FnBPA, fibronectin and IgG can also support aggregation, while IgG alone 
cannot [6]. In the case of H. pylori, aggregation is dependent on bridging by 
both vWf with GPIb and IgG with FcγRIIa [32]. Collectively it appears that 
antibody binding to a surface antigenic protein alone is insufficient to stimulate 
platelet aggregation, but that a second bridging mechanism is required. In the 
case of SdrG, it has been demonstrated that patients recovering from S. 
epidermidis infections have an increased antibody titer for SdrG [29], and 
therefore specific antibody is present in patients. We have demonstrated a 
role for IgG in platelet aggregation and that its second bridging protein is 
fibrinogen. This mechanism is analogous to that of ClfA. However ClfA binds 
to a different domain of fibrinogen. Although ClfA, ClfB and SdrG bind to 
different regions on fibrinogen, they can all support aggregation. This is not 
unreasonable as the fibrinogen molecule is large, and the areas which SdrG, 
ClfA, FnBPA or ClfB bind to do not block the RGD sites on fibrinogen which 
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are recognized by αIIbβ3. In contrast, L. lactis SdrE-induced platelet 
aggregation is dependent on a plasma factor other than fibrinogen [12] and 
thus cannot stimulate aggregation of washed platelets, even when 
supplemented with fibrinogen and IgG. This further confirms that fibrinogen 
bound to the bacterial cell is involved in the initial interaction of SdrG with 
platelets in order to promote fast aggregation. 
 
Unlike other Clf-Sdr proteins, L. lactis SdrG is able to support platelet 
adhesion directly without any plasma protein acting as a bridge. This suggests 
a direct interaction with a platelet receptor. Platelet adhesion to L. lactis SdrG 
was inhibited by tirofiban suggesting an interaction with αIIbβ3. There are a 
number of RGD-like sequences in the SdrG sequence, (79-KND-81, 404-
KLD-406, 544-KYD-546 and 549-KDD-551 in the A domain and 643-RTD-645 
in the B domain), thus we purified the extracellular A and B domains for 
further experiments. Purified A and B domain fragments of SdrG both 
supported platelet adhesion. The A domain binds fibrinogen and it was 
therefore not surprising that the weak adhesion was enhanced in the 
presence of fibrinogen. The A domain also supported enhanced adhesion in 
the presence of pooled human IgG. We therefore suggest that there are two 
independent interactions between the A domain and platelets; a fibrinogen-
 αIIbβ3 interaction, and an IgG-FcγRIIa interaction. We propose that this 
mechanism can be extrapolated to aggregation where both of these 
interactions are required for platelet signalling to take place. It is possible that 
the direct interaction is also involved in platelet aggregation, however this 
alone was insufficient to stimulate platelet aggregation because both 
fibrinogen and IgG were required to activate washed platelets (figure 2). The 
B-domain had a much stronger direct interaction with platelets that was not 
influenced by fibrinogen binding. Adhesion to the B-domain was inhibited by 
the αIIbβ3 antagonist tirofiban. The B domain contains an RGD-like sequence 
RTD (figure 4). The RGD sequence is the sequence responsible for the 
interaction between fibrinogen and the platelet receptor αIIbβ3. Therefore the 
RTD sequence in the SdrG B-domain might be responsible for the interaction 
between the SdrG B domains and platelets. We cannot rule out that there 
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may be residual levels of fibrinogen in our platelet preparation, or that the 
platelets may secrete fibrinogen during the adhesion assay, which could be 
involved in the platelet adhesion assay. The fact that the direct adhesion 
seems to be through the B-domain suggests that this is not the case, as the 
B-domain does not interact with fibrinogen. 
 
In summary, the S. epidermidis surface protein SdrG can stimulate platelet 
activation and supports platelet adhesion. It achieves this through two distinct 
mechanisms, one involving a direct interaction between the B domain and the 
platelet integrin αIIbβ3, and a second using fibrinogen and IgG as bridging 
molecules to the integrin and the FcγRIIa receptor respectively (figure 6). In 
infective endocarditis the direct interaction between SdrG and αIIbβ3 may act 
to support platelet adhesion to infected valves while the fibrinogen mediated 
interaction with αIIbβ3 leads to platelet activation and subsequent thrombus 
formation. However, as the Kd of SdrG is in the range of 90-300 nM [17, [21] 
and plasma fibrinogen levels are around 10-fold in excess of this, it is likely 
that the fibrinogen/antibody interaction is the dominant interaction in vivo. The 
binding sequence leading to platelet aggregation cannot be demonstrated, 
however platelet signalling is required for activation. Outside-in signalling 
could take place through either the direct interaction between the B-domain 
and αIIbβ3, or through antibody binding to the FcγRIIa. A further possibility is 
that the binding of fibrinogen to SdrG leads to conformational changes in the 
fibrinogen molecule, similar to changes seen when fibrinogen is immobilized 
on a solid surface, allowing it to interact with resting αIIbβ3. Once this initial 
outside-in signal takes place, inside-out signalling leads to the activation of 
αIIbβ3 allowing it to interact with soluble fibrinogen leading to crosslinking of 
platelets, resulting in aggregation. As no single initial activation stimulus alone 
was sufficient to stimulate inside-out signalling and thus aggregation, it is not 
possible to suggest which binding takes place first. A recent paper by 
Newman and co-workers demonstrated that the FcγRIIa is required for 
‘outside-in’ signaling events stimulated by platelets binding to fibrinogen [33]. 
Therefore it is possible that both interactions must take place for platelet 
activation.   
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Blocking the interaction between SdrG and platelets may abrogate the 
thrombotic complications associated with S. epidermidis infections. S. 
epidermidis strains expressing high levels of SdrG should be considered more 
pathogenic than other strains as they not only have an increased capacity to 
colonize indwelling devices conditioned with deposited fibrinogen, but also to 
support platelet adhesion and activation. Thus SdrG-expressing strains are 
likely to lead to platelet build up on indwelling devices, and possibly to further 
thrombotic complications.  
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Figure Legends 
 
Figure 1: Inhibition of platelet aggregation by the fibrinogen Bβ chain C-
terminal peptide. (A) L. lactis SdrG or L. lactis SdrE was incubated with the 
native fibrinopeptide (NEEGFFSARGHRPLD), or the control peptide 
(NEEGFFAARGHRPLD) for 10 min prior to platelet aggregation in platelet 
rich plasma (a single star represents P < 0.05, n > 3). (B) Dose response 
curve of the SAR peptide for L. lactis SdrG-induced aggregation (n > 3). (C) 
Representative aggregation trace demonstrating the effect of the SAR peptide 
at 5 and 10 mM, and the control AAR peptide at 10 mM.  
 
Figure 2: SdrG-induced platelet aggregation is dependent on fibrinogen, 
IgG and the FcγRIIa receptor. (A) Aggregations were carried out in gel 
filtered platelets supplemented with 2 mM CaCl2. Fibrinogen (1 mg/ml) and 
IgG (500 µg/ml) were supplemented back into the aggregations either 
individually or combined. L. lactis SdrG and L. lactis control were coated with 
IgG for 30 min at 37 °C and washed in TBS prior to aggregation (indicated as 
coat). The fibrinogen in this experiment was depleted of contaminating IgG 
using a Sepharose protein A column (percentage aggregation was measured 
10 min after the start of the experiment). (B) Aggregations were carried out in 
PRP. Platelets were incubated with the FcγRIIa monoclonal antibody (IV.3) or 
TBS for 10 min at 37°C prior to aggregations (Percentages were measured 5 
min after the L. lactis SdrG (control) started to aggregate, P < 0.05, n=3). (C) 
Percentage aggregation and lag times relating to (A). No aggregation 
represents a lack of aggregation response at the termination of the 
experiment at 15 min. (D) Representative platelet aggregation trace of L. 
lactis SdrG aggregation supplementation assay.  
 
Figure 3: L. lactis SdrG platelet adhesion is inhibited by αIIbβ3 
antagonists. L. lactis SdrG, L. lactis control or fibrinogen (20 µg/ml) were 
coated onto the 96-well plate and blocked with 1% BSA prior to platelet 
adhesion with GFPs supplemented with fibrinogen. Tirofiban and abciximab 
were incubated with the platelets for 10 min prior to the adhesion (n=3). 
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Repeated measures ANOVA was carried out followed by the Dunnett’s post-
test using the L. lactis SdrG adhesion as the control comparator. A single star 
denotes (P < 0.05), and a double star P < 0.01. 
 
Figure 4: SdrG sequence and structure. The overall structure of SdrG is 
outlined in the schematic in (A). (B) Represents the sequence of SdrG with 
important domains and sequences identified. The signal sequence, S, 
(residues 1-50) is followed by the fibrinogen binding A domain (residues 51-
618). The A domain is followed by the B domain which has been underlined, 
and the RGD-like sequence (RTD) is highlighted in bold. The serine-aspartate 
(SD) repeat region is highlighted in grey. The C-terminal cell wall anchoring 
LPXTG motif is underlined and highlighted in bold. The hydrophobic 
membrane-spanning domain is underlined.  
 
Figure 5: Platelets adhere directly to the B domain of SdrG. Purified 
proteins were coated onto microtiter plates at 50 µg/ml prior to platelet 
adhesion. The plates were blocked with 1% BSA, washed with TBS and then 
incubated with either TBS, fibrinogen (50 µg/ml), IgG (50 µg/ml), or IgG (50 
µg/ml) and fibrinogen (50 µg/ml) together, for 30 min at 37ºC. The plates were 
then washed and incubated with gel-filtered platelets (supplemented with 2 
mM CaCl2) for 30 min 37ºC. Data was normalized to the fibrinogen control. 
One-way ANOVA was carried out followed by the Dunnett’s post test, using 
the TBS control as the comparator (double stars represent P < 0.01, n=3).  
 
Figure 6: Schematic diagram of the interaction between S. epidermidis 
surface protein SdrG and platelets. The A domain of SdrG interacts with 
the platelet in a fibrinogen and IgG dependent manner, while the B domain 
interacts directly with αIIbβ3, likely through the RTD sequence in the B1 
domain. This direct interaction is evident during platelet adhesion, although it 
cannot support platelet aggregation.  
 21 
Tables 
Table 1: L. lactis SdrG platelet aggregation is inhibited by αIIbβ3 
antagonists and aspirin. No aggregation implies that there was no 
aggregation stimulated at 30 min. Percentage aggregation represents 
the percent aggregation at 30 min. 
 Lag Time (min) Percentage Aggregation 
L. lactis control no aggregation 0 ± 0% 
L. lactis SdrG 2.9 ± 0.5 73 ± 9% (n=5) 
   + Abciximab no aggregation 0 ± 0% (P < 0.01, n=4) 
   + Tirofiban no aggregation 1 ± 1% (P < 0.01, n=3) 
   + Aspirin no aggregation 16 ± 6% (P < 0.01, n=4) 
S. epidermidis 19 7.8 ± 3.5 67 ± 10% (n=3) 
   + Tirofiban no aggregation 0 ± 0% (P < 0.01, n=3) 
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Figure 1D 
Percentage Inhibition by peptides 
 
AAR (control) SAR  
L. lactis SdrG 13 ± 8% (NS) 83 ± 11% (P < 0.01) N=5 
L. lactis SdrE 0 ± 0%  (NS) 0 ± 0% (NS) N=3 
S. aureus Newman 5 ± 2% (NS) 3 ± 2% (NS) N=4 
Arachidonic acid 0 ± 0% (NS) 5 ± 5% (NS) N=4 
TRAP 2 ± 1% (NS) 4 ± 3% (NS) N=3 
 
Percentage Aggregation (5 min after the control starts to aggregate) 
 
PBS AAR SAR 
L. lactis SdrG 46 ± 4% (n=5) 45 ± 6% (NS, n=5) 8 ± 5% (P < 0.01, n=5) 
L. lactis SdrE 41 ± 6% (n=5) 43 ± 6%  (NS, n=3) 42 ± 3% (NS, n=3) 
S. aureus Newman 72 ± 5% (n=4) 67 ± 6% (NS, n=4) 69 ± 4% (NS, n=4) 
Arachidonic Acid 76 ± 6% (n=4) 85 ± 5% (NS, n=4) 92 ± 3% (NS, n=4) 
TRAP 93 ±2% (n=3) 90 ± 1% (NS, n=3) 92 ± 0% (NS, n=3) 
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 Fibrinogen IgG Lag time to 
aggregation 
Percentage 
aggregation 
 
L. lactis SdrG - - no aggregation 1.0 ± 0.0% N=3 
 - + no aggregation 1.0 ± 0.3% N=3 
 + - no aggregation 7.5 ± 2.5% N=4 
 + + 4.3 ± 0.9 min 62.0 ± 9.5% (P<0.01) N=4 
 + coated 1.7 ± 0.1 min 81.3 ± 6.5% (P<0.01) N=4 
L. lactis control + coated no aggregation 1.0 ± 1.0% N=4 
 + + no aggregation 5.5 ± 2.7% N=4 
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